1. Home
  2. PLG vs LPTX Comparison

PLG vs LPTX Comparison

Compare PLG & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLG
  • LPTX
  • Stock Information
  • Founded
  • PLG 2000
  • LPTX 2011
  • Country
  • PLG Canada
  • LPTX United States
  • Employees
  • PLG N/A
  • LPTX N/A
  • Industry
  • PLG
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PLG
  • LPTX Health Care
  • Exchange
  • PLG Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • PLG 133.6M
  • LPTX 119.6M
  • IPO Year
  • PLG N/A
  • LPTX N/A
  • Fundamental
  • Price
  • PLG $1.30
  • LPTX $0.48
  • Analyst Decision
  • PLG
  • LPTX Buy
  • Analyst Count
  • PLG 0
  • LPTX 3
  • Target Price
  • PLG N/A
  • LPTX $8.50
  • AVG Volume (30 Days)
  • PLG 491.7K
  • LPTX 1.5M
  • Earning Date
  • PLG 04-14-2025
  • LPTX 03-17-2025
  • Dividend Yield
  • PLG N/A
  • LPTX N/A
  • EPS Growth
  • PLG N/A
  • LPTX N/A
  • EPS
  • PLG N/A
  • LPTX N/A
  • Revenue
  • PLG N/A
  • LPTX N/A
  • Revenue This Year
  • PLG N/A
  • LPTX N/A
  • Revenue Next Year
  • PLG N/A
  • LPTX N/A
  • P/E Ratio
  • PLG N/A
  • LPTX N/A
  • Revenue Growth
  • PLG N/A
  • LPTX N/A
  • 52 Week Low
  • PLG $0.96
  • LPTX $0.47
  • 52 Week High
  • PLG $2.27
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • PLG 46.68
  • LPTX 19.00
  • Support Level
  • PLG $1.27
  • LPTX $0.47
  • Resistance Level
  • PLG $1.47
  • LPTX $0.53
  • Average True Range (ATR)
  • PLG 0.11
  • LPTX 0.04
  • MACD
  • PLG 0.01
  • LPTX 0.07
  • Stochastic Oscillator
  • PLG 23.33
  • LPTX 7.42

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: